[HTML] cell.comFull View

[HTML][HTML] Histone variant and cell context determine H3K27M reprogramming of the enhancer landscape and oncogenic state

S Nagaraja, MA Quezada, SM Gillespie, M Arzt… - Molecular cell, 2019 - cell.com
Development of effective targeted cancer therapies is fundamentally limited by our
molecular understanding of disease pathogenesis. Diffuse intrinsic pontine glioma (DIPG) is …
被引用次数：134 相关文章

[引用][C] Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State.

S Nagaraja, MA Quezada, SM Gillespie… - Molecular …, 2019 - hsrc.himmelfarb.gwu.edu
"Histone Variant and Cell Context Determine H3K27M Reprogramming of the" by Surya
Nagaraja, Michael A. Quezada et al. Home Search Browse Collections My Account About DC …

Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State.

S Nagaraja, MA Quezada, SM Gillespie, M Arzt… - Molecular cell, 2019 - folia.unifr.ch
English Development of effective targeted cancer therapies is fundamentally limited by our
molecular understanding of disease pathogenesis. Diffuse intrinsic pontine glioma (DIPG) is …
[HTML] nih.gov

[HTML][HTML] Histone variant and cell context determine H3K27M reprogramming of the enhancer landscape and oncogenic state

S Nagaraja, MA Quezada, SM Gillespie, M Arzt… - Molecular …, 2019 - ncbi.nlm.nih.gov
Development of effective targeted cancer therapies is fundamentally limited by our
molecular understanding of disease pathogenesis. Diffuse intrinsic pontine glioma (DIPG) is …

Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State.

S Nagaraja, MA Quezada, SM Gillespie, M Arzt… - Molecular …, 2019 - europepmc.org
Development of effective targeted cancer therapies is fundamentally limited by our
molecular understanding of disease pathogenesis. Diffuse intrinsic pontine glioma (DIPG) is …
[HTML] cell.com

[HTML][HTML] Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State

S Nagaraja, MA Quezada, SM Gillespie, M Arzt… - Molecular Cell, 2019 - cell.com
Development of effective targeted cancer therapies is fundamentally limited by our
molecular understanding of disease pathogenesis. Diffuse intrinsic pontine glioma (DIPG) is …

Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State.

S Nagaraja, MA Quezada, SM Gillespie, M Arzt… - Molecular cell, 2019 - sonar.ch
English Development of effective targeted cancer therapies is fundamentally limited by our
molecular understanding of disease pathogenesis. Diffuse intrinsic pontine glioma (DIPG) is …
[HTML] sciencedirect.com

[HTML][HTML] Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State

S Nagaraja, MA Quezada, SM Gillespie, M Arzt… - Molecular Cell, 2019 - Elsevier
Development of effective targeted cancer therapies is fundamentally limited by our
molecular understanding of disease pathogenesis. Diffuse intrinsic pontine glioma (DIPG) is …

Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State

S Nagaraja, MA Quezada, SM Gillespie… - Molecular …, 2019 - pubmed.ncbi.nlm.nih.gov
Development of effective targeted cancer therapies is fundamentally limited by our
molecular understanding of disease pathogenesis. Diffuse intrinsic pontine glioma (DIPG) is …

[引用][C] Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State

S Nagaraja, MA Quezada, SM Gillespie, M Arzt… - 2019